Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source offers an in-depth review of Methandrostenolone, examining its pharmacology, performance-enhancing effects, potential health risks, and legal status in various countries, while emphasizing the scientific evidence surrounding its use and misuse.

This study found that among bodybuilder-intended drugs from the black market, 33.8% of labeled products and 52.5% of steroidal oily solutions contained ingredients not matching their labels.

This study found that a significant portion of counterfeit drugs seized among bodybuilders did not match their labels, with many containing undeclared anabolic steroids or other unexpected active ingredients.

Androstenedione, a hormone supplement, doesn't improve muscle or performance and can cause harmful side effects.

In this study, researchers developed a sensitive LC–MS–MS assay to measure 3α-androstanediol levels in rat plasma and observed that testosterone raises these levels via a 5α-reductase pathway.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

In this study, engineered mice with a mutation similar to that in Olmsted syndrome showed progressive hair loss due to impaired inner root sheath keratinocyte differentiation and stem cell exhaustion.

This study reports that two oral hormonal agents, dimethandrolone undecanoate and 11β-methylnortestosterone dodecylcarbonate, may effectively suppress hormones to contraceptive levels in men with mild side effects, though longer-term trials are required to confirm their safety and efficacy.

This research suggests that fluoxymesterone, an anabolic steroid, may inhibit a key enzyme, potentially contributing to cardiovascular issues by affecting cortisol's activation of mineralocorticoid receptors.

This study concluded that the best approach for detecting Androsta-1,4,6-triene-3,17-dione administration in horses is monitoring the metabolites M1b or M4 in urine, detectable up to 77 hours post-administration.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.

In this study, daily administration of 100mg DHEA for 16 weeks in women with adequate ovarian reserve did not modify metabolic or reproductive variables, apart from increased antral follicular count and anti-Müllerian hormone levels.

This study found that a daily dose of 50 mg DHEA only slightly increased the urinary testosterone/epitestosterone ratio for a short period, without exceeding the IOC's acceptable limit.

This review discusses the cardiovascular risks associated with anabolic-androgenic steroid use and reports that, despite known toxic effects, further research is needed to clarify the causality of these risks.

This review discusses the negative effects of anabolic androgenic steroids on various organ systems in men and reports no new results, highlighting the need for physician awareness.

The document concludes that there are still unknowns about the effectiveness, risks, and detection of performance-enhancing drugs, and doping remains a challenge.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

In this study, transdermal application of anabolic steroids demonstrated rapid and extended detectability in urine, suggesting potential implications for doping control considerations.

This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

In this animal study, administering testosterone alongside a 5α-reductase inhibitor counteracted testosterone's effects on prostate enlargement while preserving its beneficial effects on muscle and bone.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This study suggests that DHT may have a less potent effect on the prostate compared to testosterone while maintaining safety and similar effects on erythropoiesis and lipids.

This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

This review highlights the potential therapeutic applications of nandrolone, an anabolic steroid, for male health, but notes that more human studies are needed due to limited existing literature.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.